In Patients with Renal Cell Carcinoma Receiving Everolimus, Acute Kidney Injury Common
the Cancer Therapy Advisor take:
According to a recent study published in the journal BMC Cancer, everolimus-induced acute kidney injury is a common adverse effect with everolimus treatment in patients with cancer and increased creatinine levels.
For the study, researchers sought to investigate the incidence of everolimus-associated acute kidney injury during treatment with everolimus in clinical practice and to identify risk factors associated with its occurrence. Researchers enrolled 110 patients with cancer who were being treated with everolimus. Of those, 84.5% had renal cell carcinoma, and the rest had other cancers.
Results showed that 23% of patients with kidney cancer developed acute kidney injury, while no patients with other cancers did. Of the 21 cases of acute kidney injury, 14 were determined to be everolimus-associated. Researchers also found that the incidence of acute kidney injury increased as baseline estimated glomerular filtration (eGFR) decreased (P = 0.029). Of the 14 patients with everolimus-associated acute kidney injury, only 1 patient discontinued everolimus due to acute kidney injury.
The rest received the drug at a decreased dose, were withheld the drug for a short period, or were discontinued due to disease progression.
The findings suggest that everolimus-associated acute kidney injury is common in patients receiving the drug for renal cell carcinoma, but occurrence of acute kidney injury may not require drug discontinuation.
Everolimus-induced acute kidney injury is a common adverse effect with everolimus treatment.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- Resveratrol and Cancer
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- Managing Chemotherapy- and Radiation Therapy-Induced Nausea and Vomiting
- Can Oncolytic Viruses Improve Immunotherapies?
- Coffee and Cancer
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
- Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
- Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
- Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling